domenica, 29 novembre 2020
Medinews
2 Marzo 2018

FDA Approves Frontline Abemaciclib for HR+/HER2- Advanced Breast Cancer

February 26, 2018 – The FDA has approved abemaciclib for use in combination with an aromatase inhibitor for the frontline treatment of postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer, according to Eli Lilly and Company, the manufacturer of the CDK4/6 inhibitor. The approval was based on data from the phase III MONARCH 3 trial in which the addition of abemaciclib to anastrozole or letrozole reduced … (leggi tutto)

TORNA INDIETRO